These findings also support targeting of mTORC2, which is activated due to the inhibition of EGFR/mTORC1/S6K signaling [53], as another therapeutic strategy to overcome EGFR TKI resistance in NSCLC cells [72]. The gene discussed is RPS6KB1; the disease is non-small cell lung carcinoma.